SCHEMBL11919923

SCHEMBL11919923

CCOc1ccc(-n2c(SCc3nc(-c4cccc(Cl)c4)no3)nnc2-c2ccncc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.76
▸ NPSR1 Q6W5P4 2/20 0.76
▸ TNKS2 Q9H2K2 8/20 0.75
▸ TNKS O95271 4/20 0.75
▸ SMN1; SMN2 Q16637 3/20 0.72
▸ TSHR P16473 1/20 0.72
▸ THRB P10828 2/20 0.70
▸ TP53 P04637 6/20 0.69
▸ LMNA P02545 2/20 0.64
▸ HTT P42858 1/20 0.64
▸ CYP3A4 P08684 1/20 0.63
▸ CYP2D6 P10635 1/20 0.63
▸ CYP2C9 P11712 1/20 0.63
▸ SULT2A1 Q06520 1/20 0.63
▸ NR5A1 Q13285 1/20 0.63
▸ AXIN2 Q9Y2T1 1/20 0.63
▸ USP2 O75604 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ MEN1 O00255 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919919 0.88 ALDH1A1 (0.73) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL11919922 0.84 THRB (0.60) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL1544573 0.82 SMN1; SMN2 (0.59) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL1544545 0.82 LMNA (0.70) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL11919903 0.81 TP53 (1.00) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL16010756 0.81 TNKS2 (1.00) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL11919901 0.79 TP53 (1.00) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL11919929 0.78 NPSR1 (0.69) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL11919898 0.78 TNKS2 (1.00) MAPTNPSR1TNKS2TNKSSMN1; SMN2
SCHEMBL1544492 0.78 LMNA (0.57) MAPTNPSR1TNKS2TNKSSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 — — US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 — — US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 — — US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 MAPT 2763/4885NPSR1 4727/4885TNKS2 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback